Recently, early increase in inflammatory cytokine levels in the presence of a PD-L1 checkpoint inhibitor was shown to be predictive of the efficacy of the inhibitor in patients with NSCLC (Ozawa et al. 2019). The gene discussed is CD274; the disease is non-small cell lung carcinoma.